Literature DB >> 25224526

American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome.

David S Weinberg1, Walter Smalley2, Joel J Heidelbaugh3, Shahnaz Sultan4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25224526     DOI: 10.1053/j.gastro.2014.09.001

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  35 in total

1.  Update on Irritable Bowel Syndrome Guidelines.

Authors:  Brian E Lacy
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-12

2.  Advances in IBS 2016: A Review of Current and Emerging Data.

Authors:  Philip S Schoenfeld
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-08

Review 3.  Gut microbiota and bipolar disorder: a review of mechanisms and potential targets for adjunctive therapy.

Authors:  Shakuntla Gondalia; Lisa Parkinson; Con Stough; Andrew Scholey
Journal:  Psychopharmacology (Berl)       Date:  2019-04-30       Impact factor: 4.530

Review 4.  Diagnosis and management of functional symptoms in inflammatory bowel disease in remission.

Authors:  Carlos Teruel; Elena Garrido; Francisco Mesonero
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 5.  The place of eluxadoline in the management of irritable bowel syndrome with diarrhea.

Authors:  Sherry Levio; Brooks D Cash
Journal:  Therap Adv Gastroenterol       Date:  2017-07-24       Impact factor: 4.409

6.  Irritable Bowel Syndrome.

Authors:  Kristen Ronn Weaver; Gail DʼEramo Melkus; Wendy A Henderson
Journal:  Am J Nurs       Date:  2017-06       Impact factor: 2.220

Review 7.  Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.

Authors:  Nicholas J Talley; Gerald Holtmann; Marjorie M Walker
Journal:  J Gastroenterol       Date:  2015-04-29       Impact factor: 7.527

8.  New and Emerging Treatment Options for Irritable Bowel Syndrome.

Authors:  Brian E Lacy; William D Chey; Anthony J Lembo
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-04

9.  Value-based Pricing for Rifaximin Increases Access of Patients With Irritable Bowel Syndrome With Diarrhea to Therapy.

Authors:  Eric D Shah; Sameer D Saini; William D Chey
Journal:  Clin Gastroenterol Hepatol       Date:  2019-03-01       Impact factor: 11.382

10.  Eluxadoline (Viberzi): A Mu-Opioid Receptor Agonist for the Treatment Of Irritable Bowel Syndrome With Diarrhea.

Authors:  Fraidy Maltz; Brooke Fidler
Journal:  P T       Date:  2017-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.